US › Healthcare

TriSalus Life Sciences Inc. (TLSI)

US · Healthcare · Medical Devices

$4.90-0.61%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$11.4M

Revenue YoY

+1.7%

Net profit

$-9.2M

EPS

$-0.16

EPS estimate

$-0.15

Net margin

-80.5%

EPS came in at -0.16 against a street estimate of -0.15 — a miss of 6.7%.

Key statistics

Market cap

$289.4M

Forward P/E

0.0

P/B

44.84

Book value

$0.11

EPS (TTM)

$-1.31

52-week high

$7.95

52-week low

$2.20

50-day MA

$4.74

200-day MA

$4.84

Beta

0.44

Analyst view

Analysts rate TriSalus Life Sciences Inc. a strong buy (8 buy, 0 hold, 0 sell out of 8) with an average price target of $10.00.

Shareholding

Insiders

33.96%

Institutions

35.71%

Largest institutional holders

Fund	Stake
First Light Asset Management, LLC	10.64%
Awm Investment Company Inc	3.38%
Nantahala Capital Management, LLC	3.36%
BlackRock Inc	2.44%
Vanguard Capital Management, LLC	2.19%
Gilder Gagnon Howe & CO LLC	1.44%
HPM Partners LLC	1.28%
Geode Capital Management, LLC	1.26%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for TriSalus Life Sciences Inc. — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.